Article

TBI Followed by GVHD Prophylaxis Decreases the Incidence of GVHD in Hematologic Malignancies

Author(s):

Myeloablative transplantation with a total body irradiation regimen followed by a graft-versus-host disease prophylaxis regimen led to a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies.

Myeloablative transplantation with a total body irradiation (TBI) regimen followed by a graft-versus-host disease (GVHD) prophylaxis regimen led to a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies, according to data presented at the 2022 Transplantation & Cellular Therapy Meetings.

In the phase 2 trial, 63 patients were treated with TBI or busulfan (Busuflex) followed by a GVHD prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus, and mycophenolate mofetil (MMF) following allogeneic hematopoietic cell transplantation (HCT). The primary end point was cumulative incidence of chronic GVHD requiring systemic immunosuppressive treatment at 1 year after transplant.

At 1 year of follow-up, only 2 patients (0.031%) developed chronic GVHD requiring immune suppression; 1 patient in the MRD group and 1 patient in the MUD group, both of whom received peripheral blood stem cell graft.

Following HCT, investigators employed a myeloablative conditioning regimen of TBI at a total dose of 1320 cGy administered twice daily from days -4 to -1. Patients who were unable to receive further radiation received busulfan 3.2 mg/kg daily for a cumulative area under the concentration time curve of 19,000 to 21,000 µmol/min/L plus fludarabine 160 mg/m2 on days -5 to -2. Patients then underwent a GVHD prophylaxis regimen consisting of PTCy (50 mg/kg on days 3 and 4), tacrolimus (beginning at day 5), and MMF (beginning at day 5).

Most patients in the analysis were males (52%) and were over the age of 18 (83%). The median age of patients included in the analysis was 36 (range, 2-55) and the median follow up was 502 days post-HCT.

Patients had a comorbidity by the HCT-comorbidity index of low, intermediate, or high at a rate of 46%, 37%, and 17%, respectively. The most common diagnoses included acute lymphoblastic leukemia (38%), acute myeloid leukemia (35%), and myelodysplastic syndromes (11%).

All 63 patients achieved primary neutrophil engraftment by 42 days, with a median of 16 days (range, 13-27). Almost all patients (94%) experienced platelet engraftment by 6 months, with a median of 25 days (range, 16-98). By day 100, 86% of patients had achieved full donor bone marrow chimerism and 95% had achieved full donor peripheral blood CD3 and CD33 chimerism (both defined as > 95% donor DNA).

Further results from the study showed that the overall cumulative incidence of grade 2-4 active GVHD by 100 days post-transplant was 14% overall (95% CI, 6%-23%), including 7% in the MRD group and 32% in the MUD group. The incidence of grade 3/4 acute GVHD was 5% (95% CI, 0%-10%) and was found to be similar in both the MRD and MUD arms.

The estimated 2-year overall survival rate was 79% (95% CI, 65%-88%), with a 75% rate in the MRD group and a 95% rate in the MUD group. The estimated 2-year GVHD-free relapse survival rate was 57% (95% CI, 42%-69%), 56% in the MRD group and 63%, in the MUD group.

The 2-year cumulative estimated incidence of relapse was 22% in the MRD arm and 16% in the MUD arm, for a total of 21% overall. Finally, the 2-year cumulative incidence of non-relapse mortality was 13% overall, with a 15% and 5% rate in the MRD and MUD groups, respectively.

In terms of safety, 66% of patients needed total parenteral nutrition for oral mucositis and regimen-related toxicities during their initial transplant admission.

Study authors concluded that the regimen was feasible and effective for both adult and pediatric patients. They also added that a further improvement in outcomes could be reached through incorporating post-transplant mitigating strategies with supportive care to combat the toxicities related to the regimen.

Reference

El Jurdi N, O’Leary D, He F, et al. Low incidence of chronic graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide using matched related or unrelated donors: phase II study interim analysis. Presented at: 2022 Transplantation and Cellular Therapy Meetings; April 22-26, 2022; Salt Lake City, UT. Abstract 370.

Related Videos
Aditya Bardia, MD, MPH, FASCO, professor, Department of Medicine, Division of Hematology/Oncology, director, Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
John M. Burke, MD
Eunice S. Wang, MD
Rachel E. Rau, MD
Timothy S. Fenske, MD, MS
Dasom (Caroline) Lee, MD
Christina Poh, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
C. Ola Landgren, MD, PhD